View Future GrowthZYUS Life Sciences 과거 순이익 실적과거 기준 점검 0/6ZYUS Life Sciences 의 수입은 연평균 -10.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 10.7%의 비율로 증가했습니다. 매출은 연평균 26.6%의 비율로 증가해 왔습니다.핵심 정보-10.40%순이익 성장률3.87%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률26.63%자기자본이익률n/a순이익률-7,256.77%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 14ZYUS Life Sciences to Discontinue International Operations Amid Strategic RealignmentZYUS Life Sciences Corporation announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. As part of this realignment, the Company will streamline operations by discontinuing its international business development activities. This decision is intended to reduce overhead costs and redirect resources toward the Company's drug development programs. The Company will also initiate a formal wind-down of its international legal entities.공고 • Jun 13Zyus Life Sciences Corporation's Chief Strategy and Investment Officer Keith Carpenter to Step Down, Effective June 11, 2026ZYUS Life Sciences Corporation announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. In connection with this strategic realignment, Keith Carpenter, Chief Strategy and Investment Officer, will step down from his role, effective June 11, 2026. A key member of the Company's executive team since 2018, Mr. Carpenter was an instrumental figure in many facets of the business over the past eight years.공고 • May 29ZYUS Life Sciences Corporation announced that it has received CAD 0.265 million in funding and other investors.ZYUS Life Sciences Corporation announced that it has raised CAD 265,000 in a round of funding on May 28, 2026. The company received secured Loan in the transaction.공고 • May 26ZYUS Life Sciences Corporation, Annual General Meeting, Jul 24, 2026ZYUS Life Sciences Corporation, Annual General Meeting, Jul 24, 2026.공고 • Apr 18Zyus Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2A Utopia-1 Trial Evaluating Novel Non-Opioid Pain DrugZYUS Life Sciences Corporation announced that the last patient has completed the final study visit in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating efficacy of Trichomylin softgel capsules in patients experiencing moderate to severe cancer-related pain. UTOPIA-1 trial is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With the completion of the final study visit, the Phase 2a UTOPIA-1 trial has reached the last patient last visit milestone. Top-line results from the Phase 2a UTOPIA-1 trial are expected to be reported in Q2, following completion of data cleaning and analysis. These findings will build on the encouraging preliminary data previously announced that suggested Trichomylin softgel capsules was effective for pain management, safe and well tolerated, and indicated potential for opioid-sparing.공고 • Mar 06+ 1 more updateZYUS Life Sciences Corporation announced that it has received CAD 0.5 million in fundingZYUS Life Sciences Corporation announced that it has issued an unsecured promissory note in the principal amount of CAD 500,000 to an arm's-length third party lender on March 5, 2026. The note bears interest at a rate of 12% per annum from the date of issuance, calculated on a simple basis, and matures on August 5, 2026. Interest on the note is payable at maturity. The note is not convertible to equity, and the company may prepay this note, including accrued interest, at any time without penalty or premium.공고 • Feb 25ZYUS Life Sciences Corporation announced that it expects to receive CAD 7 million in fundingZYUS Life Sciences Corporation announced a non-brokered private placement of 11,111,111 Units of the company at a price of CAD 0.63 for gross proceeds of CAD 7,000,000 on February 24, 2026. Each Unit will consist of one common share of the Company and one-half (1/2) of one Common Share purchase warrant at an exercise price of CAD 0.85 for a period of 24 months from the date of issuance. In connection with the private placement, the Company may pay certain eligible finders a cash fee in respect of the gross proceeds raised under the private placement.공고 • Jan 12ZYUS Life Sciences Corporation announced that it expects to receive CAD 16 million in fundingZYUS Life Sciences Corporation announces a brokered private placement of a minimum of 23,809,523 units of the Company and up to a maximum of 25,396,825 Units at a price of CAD 0.63 per Unit for minimum gross proceeds of CAD 15,000,000 and maximum gross proceeds of up to CAD 16,000,000 on January 12, 2026. Each unit will be comprised of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.85 for a period of 24 months from the date of issuance. Closing of the LIFE Offering is expected to occur on or about January 29, 2026, or such other date as the Company and the Lead Agent may agree, subject to receipt of all necessary regulatory approvals, including approval of the TSXV. In Connection with the LIFE Offering, the Company has agreed to pay the Agents a cash commission of 5.0% of the gross proceeds of the LIFE Offering, and to issue Agents’ warrants equal to 5.0% of the number of Units sold under the LIFE Offering, each Agents’ warrant exercisable for one Common Share at the Offering Price for a period of 36 months from the date of issuance. Subscriptions from purchasers on the President’s List up to a maximum of CAD 5,000,000 will be subject to reduced compensation of 2.5% cash commission and 2.5% Agents’ warrants. In addition, the Company will pay the Lead Agent a corporate finance fee consisting of (i) a cash fee equal to 2.0% of the gross proceeds of the LIFE Offering and (ii) corporate finance warrants equal to 2.0% of the number of Units sold under the LIFE Offering, in each case excluding President’s List subscriptions.공고 • Jan 08ZYUS Life Sciences Corporation Reports Preliminary Results from Ongoing Phase 2A UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain DrugZYUS Life Sciences Corporation announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin®? softgel capsules in patients experiencing moderate to severe cancer-related pain. Preliminary results Highlights. UTOPIA-1 is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Preliminary results from Phase 2a are based on data from the first 25% of enrolled patients who have completed treatment in the UTOPIA-1 trial. Early data suggest a reduction in average daily pain, pain interference, and pain severity; a reduction in opioid dosing for breakthrough pain; and no serious adverse events related to Trichomylin® softgel capsules. Trichomylin® softgel capsules were generally well tolerated, with the majority of adverse reactions being expected, mild, and occurring during dose titration, consistent with the Company's Phase 1 Z-TRI-10001 trial (NCT04867057).공고 • Nov 08ZYUS Life Sciences Corporation announced that it expects to receive CAD 1.5 million in fundingZYUS Life Sciences Corporation announces 2,307,692 units at a price of CAD 0.65 per Unit for gross proceeds of up to CAD 1,500,000 on November 7, 2025. Each Unit consists of one common share of the Company and one Common Share purchase warrant, whereby each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. No finder's fees were paid in connection with the Offering. All securities issued by way of the First Tranche are subject to a hold period expiring March 7, 2026, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. On the same day, It has issued 1,923,077 Units at a price of CAD 0.65 for gross proceeds of CAD 1,250,000.05.공고 • Oct 22ZYUS Life Sciences Corporation announced that it has received fundingOn October 20, 2025, The company has closed the transaction. The company has amended the terms of the transaction. The company has issued 724,637 common share purchase warrants at an exercise price of $0.69 per common share until the expiry date. he Loan bears interest at an annual rate of 12%, is payable on maturity, is pre-payable by the Company at any time without penalty or premium and will mature on October 31, 2027.공고 • Oct 03Zyus Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2A Utopia-1 Cancer Pain TrialZYUS Life Sciences Corporation announced the activation of two additional clinical sites in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial. The addition of CancerCare Manitoba ("CCMB") and The Research Institute of the McGill University Health Centre ("The Institute"), along with the Centre Hospitalier de l'Université de Montréal ("CHUM"), expands the Phase 2a UPOPIA-1 trial to three active clinical sites across Canada. UTOPIA-1 is a single-arm, proof-of-concept study designed to evaluate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With three active sites, the trial is positioned to broaden diversity of trial participants and accelerate patient enrollment in the Phase 2a UTOPIA-1 trial evaluating Trichomylin softgel capsules.공고 • Jul 31ZYUS Life Sciences Corporation announced that it expects to receive CAD 1 million in fundingZYUS Life Sciences Corporation announced a non brokered private placement to issue 1,408,450 Units at a price of CAD 0.71 per unit for aggregate gross proceeds of CAD 999,999.5 on July 29, 2025. Each Unit consists of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. On the same day the company issued 450,281 Units at a price of CAD 0.71 for aggregate proceeds of CAD 319,699.51 in its first tranche. All securities issued in the First Tranche are subject to a hold period expiring November 30, 2025, in accordance with applicable securities laws and the policies of the TSXV.공고 • Jul 15ZYUS Life Sciences Corporation Appoints Dr. Julie Stakiw, MD, FRCPC as Chief Medical Officer, Effective July 14, 2025ZYUS Life Sciences Corporation announced the appointment of Dr. Julie Stakiw, MD, FRCPC, to the Company's leadership team as Chief Medical Officer (CMO), effective July 14, 2025. Dr. Stakiw is a prominent hematologist-oncologist with over two decades of clinical and academic experience based in Saskatoon, Saskatchewan, specializing in blood cancers and stem cell transplantation. As CMO, Dr. Stakiw will provide clinical leadership and oversee the scientific integrity of ZYUS' clinical development program. Her appointment marks a significant step as the Company advances its lead drug product candidate, Trichomylin® softgel capsules, through its pivotal Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) trial. Dr. Stakiw completed her medical degree and internal medicine residency at the University of Saskatchewan, followed by specialized training in hematology at Queen's University and a clinical fellowship in lymphoma and stem cell transplantation at Princess Margaret Hospital in Toronto. She has held several key leadership positions including Provincial Leader of Hematology, Medical Director of Saskatchewan's Blood and Marrow Transplant Program, and Medical Director of the Saskatoon Cancer Clinic. Dr. Stakiw also previously served as Director of Clinical Trials at a regional cancer centre in Ontario and as Director of Patient Research and Innovation for the Saskatchewan Cancer Agency. Known for her patient-centered approach andexpertise in managing complex hematologic conditions such as multiple myeloma and leukemia, Dr. Stakiw continues to serve as a Clinical Professor in Hematological Oncology at the University of Saskatchewan while maintaining an active clinical practice. Her extensive clinical and leadership experience will be instrumental in advancing ZYUS' clinical development program. Dr. Stakiw succeeds Dr. Lionel Marks de Chabris, who is stepping down as CMO and will continue to provide strategic guidance as Chair of the Clinical Research Advisory Committee. The Company is grateful for Dr. Marks de Chabris's ongoing leadership and commitment to advancing ZYUS' mission.공고 • Jun 29ZYUS Life Sciences Corporation announced that it has received CAD 0.747899 million in fundingOn June 27, 2025, ZYUS Life Sciences Corporation closed the transaction. The company issued 746,267 units at an issue price of CAD 0.67 for gross proceeds of CAD 499,998.89 in its second and final tranche. The company issued a total of 1,116,267 units at a price of CAD 0.67 per unit for gross proceeds of CAD 747,898.89 in the offering. No finder’s fees were paid in connection with the offering. All securities issued under the second tranche are subject to a hold period expiring October 28, 2025, in accordance with applicable securities laws and the policies of the TSXV. The offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. Certain insiders of the company participated in the offering and acquired 746,267 units for CAD 499,998.89. The offering was approved by the directors of the company who are independent in respect of the offering and who are not employees of the company.공고 • Jun 17ZYUS Life Sciences Corporation announced that it expects to receive CAD 0.749999 million in fundingZYUS Life Sciences Corporation announced a non-brokered private placement to issue 1,119,402 Units of the company at a price of CAD 0.67 for aggregate gross proceed of CAD 749,999.34. Each Unit consists of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. The transaction is subject to the approval of the TSXV. On the same date, the company issued 370,000 Units at a price of CAD 0.67 for aggregate gross proceeds of CAD 247,900.00 in its first Tranche. All securities issued under the First Tranche are subject to a hold period expiring October 17, 2025.공고 • May 22Zyus Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain DrugZYUS Life Sciences Corporation announced it is in the process of finalizing site initiation for the initial locations to be used in its Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial. The Phase 2 UTOPIA clinical trial will consist of Phase 2A ("UTOPIA-1") and Phase 2B ("UTOPIA-2). UTOPIA-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin®? softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population. Patient enrollment for UTOPIA-1 is expected to begin in early June 2025, across multiple sites in Canada, with interim data from UTOPIA-1 anticipated mid-summer 2025. ZYUS' announcement comes at a time of growing global recognition of the untapped potential of cannabinoids in oncology. A meta-analysis of medial cannabis outcomes and associations with cancer published in Frontiers in Oncology on April 14, 2025, analyzed over 10,000 peer-reviewed studies encompassing 39,767 data points. The findings revealed a "strong consensus" supporting cannabinoids for managing cancer-related symptoms.공고 • May 16ZYUS Life Sciences Corporation announced that it has received CAD 1.375 million in fundingOn May 15, 2025, ZYUS Life Sciences Corporation has closed its second and final tranche. The company has issued 871,212 Units at a price of CAD 0.66 per unit for gross proceeds of CAD 574,999.92.The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering is approximately CAD 1,370,000. The Company issued a total of 2,083,333 Units each priced at CAD 0.66 per Unit in the Offering. Each Unit consists of one common share of the Company and one-half of one Common Share purchase warrant, whereby each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.94 for a period of 24 months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. No finder’s fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring September 7, 2025 and all securities issued under the Second Tranche are subject to a hold period expiring September 16, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV.공고 • May 01ZYUS Life Sciences Corporation announced that it expects to receive CAD 2 million in fundingZYUS Life Sciences Corporation announced a non-brokered private placement to issue up to 3,030,303 units at an issue price of CAD 0.66 per unit for the aggregate gross proceeds of CAD 1,999,999.98 on May 1, 2025. Each unit is comprised of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to acquire one common share at a price of CAD 0.94 for a period of twenty-four months from the date of issuance. No finders fees will be paid in connection with the offering. The transaction is expected to close over multiple tranches as the corporation may determine from time to time, with the first tranche expected to close on or about May 6, 2025. The transaction is subject to customary conditions including, but not limited to, receipt of all necessary TSX Venture Exchange , regulatory and other approvals. Securities offered are subject to hold period of four months plus a day from the date of issuance.공고 • Apr 21ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2025ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2025.공고 • Aug 27ZYUS Life Sciences Corporation announced that it has received CAD 3.334828 million in fundingZYUS Life Sciences Corporation announced a non-brokered private placement of 3,510,345 units at a price of CAD 0.95 per unit for the gross proceeds of CAD 3,334,828 on August 26, 2024. Each unit consists of one common share of the company and one common share purchase warrant, whereby each warrant entitles the holder to acquire one common share at a price of CAD 1.30 for a period of twenty-four months from the date of issuance. Insiders of the company, who are independent directors, purchased 842,103 Units pursuant to the private placement for gross proceeds of CAD 800,000. All securities issued pursuant to the Private Placement are subject to a statutory hold period expiring four months plus a day from the date of issuance in accordance with applicable securities legislation in Canada. The Private Placement remains subject to the final acceptance of TSX Venture Exchange (“TSXV”).공고 • Jun 05ZYUS Life Sciences Receives Cannabis Drug License from Health CanadaZYUS Life Sciences Corporation announced that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a Cannabis Drug License issued pursuant to the Cannabis Act (Canada) and Cannabis Regulations. This license pertains specifically to its processing facility located in Saskatoon, Saskatchewan, which is dedicated to the manufacture of pharmaceutical-grade cannabinoid formulations. Issuance of the Cannabis Drug License compliments ZYUS’ existing standard processing, research, analytical and medical sales licenses and expands the scope of the Company’s license portfolio by enabling ZYUS to manufacture and distribute drugs containing cannabinoids for Health Canada-approved clinical trials in Canada. Advancing Innovation Through Trichomylin Softgel Capsules Phase 2 Clinical Trial: As previously announced, ZYUS intends to launch a Phase 2 Clinical Trial in Canada later this year to assess the preliminary efficacy, safety, and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. ZYUS’ receipt of the Cannabis Drug License and compliance with applicable quality guidelines issued by the International Council for Harmonisation and Good Manufacturing Practice standards provides a robust framework respecting the Company’s manufacture of Trichomylin softgel capsules for its Phase 2 Clinical Trial and brings ZYUS one step closer to achieving its goal of obtaining regulatory approval of its proprietary drug product.공고 • Apr 14ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2024ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2024. Agenda: Annual General and Special meeting.공고 • Feb 02Zyus Appoints Dr. Hance Clarke as Clinical Advisory CommitteeZYUS Life Sciences Corporation announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee. Dr. Clarke’s extensive background in healthcare and pain management aligns seamlessly with the committee's mission to provide valuable insights and strategic guidance to ZYUS’ clinical trial programs. Dr. Clarke is internationally recognized for his outstanding contributions to research productivity and advancements in patient care. He holds the positions of Director of Pain Services at the GoodHope Ehlers Danlos Clinic and the Pain Research Unit at Toronto General Hospital. Additionally, he serves as associate professor in the Department of Anesthesiology and Pain Medicine at the University of Toronto. In his capacity as the Knowledge Translation Chair for the University of Toronto Centre for the Study of Pain, Dr. Clarke demonstrates a strong commitment to advancing the understanding and application of pain research. With over 170 peer-reviewed publications to his credit, he currently holds the position of president-elect of the Canadian Pain Society and serves as the president of the Canadian Consortium for the Investigation of Cannabinoids. Dr. Clarke has also played a leading role in educating the Canadian public about pain control, risk factors for chronic opioid use, alternatives to opioids and the need for further studies on understanding the beneficial and adverse effects of cannabis. Being a public champion of evidence-based solutions for the opioid crisis and a national pain and addictions strategist, Dr. Clarke’s appointment aligns with ZYUS’ clinical research initiatives and his influential insights in this field will offer valuable guidance to further enhance ZYUS’ clinical programs. Dr. Clarke joins previously-appointed Advisory Committee members: ZYUS’ Chief Medical Officer, Dr. Lionel Marks de Chabris, Chair of the Committee; Dr. Mary Lynch, Director of Research at the Pain Management Unit at the Queen Elizabeth II Health Sciences Centre; Dr. Cedric Francois, Co-Founder, Chief Executive Officer and President of Apellis Pharmaceuticals; Dr. Alice Zwerling, Assistant Professor in the School of Epidemiology and Public Health in the Faculty of Medicine at the University of Ottawa; and, Ms. Audrey Haukioja, a seasoned executive with over 25 years of experience in the pharmaceutical field, specializing in clinical trials and drug development.공고 • Dec 05ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain ManagementZYUS Life Sciences Corporation announced that it has made the strategic decision to proceed with a Phase 2 Clinical Trial in Canada to assess the preliminary efficacy, safety and tolerability of Trichomylin®? softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Transitioning to Phase 2 Clinical Trial for Trichomylin Softgels: Initially planned as a Phase 2a Clinical Trial, ZYUS has made the strategic decision to fast-track and progress directly to a full Phase 2 Clinical Trial following receipt of positive results from its Phase 1, first-in-human clinical trial testing the safety and tolerability of Trichomylin softgel capsules. While a Phase 2a Clinical Trial could have provided preliminary efficacy data for Trichomylin softgels, it would not have generated the data required by regulatory agencies in Canada and the U.S. to formally commence the regulatory drug approval process and, therefore, completion of a Phase 2b clinical trial would have been necessary. In addition to efficiently building shareholder value, ZYUS believes advancing directly to a full Phase 2 Clinical Trial will also reduce the time and cost associated with obtaining regulatory approval of Trichomylin softgel capsules and delivering this important therapeutic to patients in need. Phase 2 Clinical Trial Structure: ZYUS has selected a leading, full-service Canadian contract research organization with extensive clinical trial management experience to conduct its Phase 2 Clinical Trial. ZYUS anticipates the trial will be structured as a double-blinded, placebo-controlled, randomized, multiple dose escalation study that will enroll a total of up to 126 patients with advanced cancer and moderate to severe cancer-related pain. The company plans to recruit patients at six Canadian investigative sites, with patients being randomized at a 1:1 ratio with approximately 63 patients in each arm.공고 • Nov 24ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® SoftgelsZYUS Life Sciences Corporation announced receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (“FIH”) Clinical Trial for its lead drug product candidate, Trichomylin® softgels.공고 • Oct 25ZYUS Life Sciences Corporation Appoints Tim Miller as Director of Investor Relations and Capital Markets, Effective November 1, 2023ZYUS Life Sciences Corporation announced that Tim Miller is joining the Company as Director of Investor Relations and Capital Markets, effective November 1, 2023. Mr. Miller will be based out of the Company’s Toronto office and brings a wealth of knowledge, experience and expertise to his new role with ZYUS, making him a valuable addition to the team. Mr. Miller is a distinguished professional with a Bachelor of Commerce degree from Ryerson University, boasting an impressive track record of nearly two decades as a capital markets executive. His core focus has been Institutional Equity Sales, and his expertise extends across a broad spectrum of clients. These encompass a wide range, from US and Canadian family offices to hedge funds, pension funds, mutual funds, venture capital firms, and private equity investors.공고 • Sep 02ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member, Wayne Brownlee and Announces Reconstitution of its Board CommitteesZYUS Life Sciences Corporation announced that Wayne Brownlee, who was conditionally appointed to the Company’s Board of Directors on June 28, 2023, has successfully obtained from Health Canada security clearance required to serve as a director of the Corporation pursuant to the Cannabis Act (Canada). With the appointment of Wayne Brownlee taking effect, the Company’s Board of Directors reconstituted its board committees as follows: Audit Committee: John Knowles (Chair), Garnette Weber and Wayne Brownlee. Compensation Committee: Garnette Weber (Chair), Richard Hoyt and Dr. Charlotte Moore Hepburn. Governance and Nominating Committee: Richard Hoyt (Chair), John Knowles, Brent Zettl and Wayne Brownlee.매출 및 비용 세부 내역ZYUS Life Sciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:ZLSC.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비30 Sep 250-348230 Jun 250-348331 Mar 250-349231 Dec 240-349230 Sep 240-3711230 Jun 240-3712231 Mar 240-4113131 Dec 230-4313130 Sep 230-2411130 Jun 230-2710131 Mar 230-249231 Dec 220-259230 Sep 220-2610331 Dec 210-23135양질의 수익: ZLSC.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: ZLSC.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ZLSC.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 10.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ZLSC.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ZLSC.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ZLSC.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/17 20:39종가2026/06/10 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ZYUS Life Sciences Corporation는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Justin KeywoodStifel Canada
공고 • Jun 14ZYUS Life Sciences to Discontinue International Operations Amid Strategic RealignmentZYUS Life Sciences Corporation announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. As part of this realignment, the Company will streamline operations by discontinuing its international business development activities. This decision is intended to reduce overhead costs and redirect resources toward the Company's drug development programs. The Company will also initiate a formal wind-down of its international legal entities.
공고 • Jun 13Zyus Life Sciences Corporation's Chief Strategy and Investment Officer Keith Carpenter to Step Down, Effective June 11, 2026ZYUS Life Sciences Corporation announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. In connection with this strategic realignment, Keith Carpenter, Chief Strategy and Investment Officer, will step down from his role, effective June 11, 2026. A key member of the Company's executive team since 2018, Mr. Carpenter was an instrumental figure in many facets of the business over the past eight years.
공고 • May 29ZYUS Life Sciences Corporation announced that it has received CAD 0.265 million in funding and other investors.ZYUS Life Sciences Corporation announced that it has raised CAD 265,000 in a round of funding on May 28, 2026. The company received secured Loan in the transaction.
공고 • May 26ZYUS Life Sciences Corporation, Annual General Meeting, Jul 24, 2026ZYUS Life Sciences Corporation, Annual General Meeting, Jul 24, 2026.
공고 • Apr 18Zyus Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2A Utopia-1 Trial Evaluating Novel Non-Opioid Pain DrugZYUS Life Sciences Corporation announced that the last patient has completed the final study visit in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating efficacy of Trichomylin softgel capsules in patients experiencing moderate to severe cancer-related pain. UTOPIA-1 trial is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With the completion of the final study visit, the Phase 2a UTOPIA-1 trial has reached the last patient last visit milestone. Top-line results from the Phase 2a UTOPIA-1 trial are expected to be reported in Q2, following completion of data cleaning and analysis. These findings will build on the encouraging preliminary data previously announced that suggested Trichomylin softgel capsules was effective for pain management, safe and well tolerated, and indicated potential for opioid-sparing.
공고 • Mar 06+ 1 more updateZYUS Life Sciences Corporation announced that it has received CAD 0.5 million in fundingZYUS Life Sciences Corporation announced that it has issued an unsecured promissory note in the principal amount of CAD 500,000 to an arm's-length third party lender on March 5, 2026. The note bears interest at a rate of 12% per annum from the date of issuance, calculated on a simple basis, and matures on August 5, 2026. Interest on the note is payable at maturity. The note is not convertible to equity, and the company may prepay this note, including accrued interest, at any time without penalty or premium.
공고 • Feb 25ZYUS Life Sciences Corporation announced that it expects to receive CAD 7 million in fundingZYUS Life Sciences Corporation announced a non-brokered private placement of 11,111,111 Units of the company at a price of CAD 0.63 for gross proceeds of CAD 7,000,000 on February 24, 2026. Each Unit will consist of one common share of the Company and one-half (1/2) of one Common Share purchase warrant at an exercise price of CAD 0.85 for a period of 24 months from the date of issuance. In connection with the private placement, the Company may pay certain eligible finders a cash fee in respect of the gross proceeds raised under the private placement.
공고 • Jan 12ZYUS Life Sciences Corporation announced that it expects to receive CAD 16 million in fundingZYUS Life Sciences Corporation announces a brokered private placement of a minimum of 23,809,523 units of the Company and up to a maximum of 25,396,825 Units at a price of CAD 0.63 per Unit for minimum gross proceeds of CAD 15,000,000 and maximum gross proceeds of up to CAD 16,000,000 on January 12, 2026. Each unit will be comprised of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.85 for a period of 24 months from the date of issuance. Closing of the LIFE Offering is expected to occur on or about January 29, 2026, or such other date as the Company and the Lead Agent may agree, subject to receipt of all necessary regulatory approvals, including approval of the TSXV. In Connection with the LIFE Offering, the Company has agreed to pay the Agents a cash commission of 5.0% of the gross proceeds of the LIFE Offering, and to issue Agents’ warrants equal to 5.0% of the number of Units sold under the LIFE Offering, each Agents’ warrant exercisable for one Common Share at the Offering Price for a period of 36 months from the date of issuance. Subscriptions from purchasers on the President’s List up to a maximum of CAD 5,000,000 will be subject to reduced compensation of 2.5% cash commission and 2.5% Agents’ warrants. In addition, the Company will pay the Lead Agent a corporate finance fee consisting of (i) a cash fee equal to 2.0% of the gross proceeds of the LIFE Offering and (ii) corporate finance warrants equal to 2.0% of the number of Units sold under the LIFE Offering, in each case excluding President’s List subscriptions.
공고 • Jan 08ZYUS Life Sciences Corporation Reports Preliminary Results from Ongoing Phase 2A UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain DrugZYUS Life Sciences Corporation announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin®? softgel capsules in patients experiencing moderate to severe cancer-related pain. Preliminary results Highlights. UTOPIA-1 is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Preliminary results from Phase 2a are based on data from the first 25% of enrolled patients who have completed treatment in the UTOPIA-1 trial. Early data suggest a reduction in average daily pain, pain interference, and pain severity; a reduction in opioid dosing for breakthrough pain; and no serious adverse events related to Trichomylin® softgel capsules. Trichomylin® softgel capsules were generally well tolerated, with the majority of adverse reactions being expected, mild, and occurring during dose titration, consistent with the Company's Phase 1 Z-TRI-10001 trial (NCT04867057).
공고 • Nov 08ZYUS Life Sciences Corporation announced that it expects to receive CAD 1.5 million in fundingZYUS Life Sciences Corporation announces 2,307,692 units at a price of CAD 0.65 per Unit for gross proceeds of up to CAD 1,500,000 on November 7, 2025. Each Unit consists of one common share of the Company and one Common Share purchase warrant, whereby each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. No finder's fees were paid in connection with the Offering. All securities issued by way of the First Tranche are subject to a hold period expiring March 7, 2026, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. On the same day, It has issued 1,923,077 Units at a price of CAD 0.65 for gross proceeds of CAD 1,250,000.05.
공고 • Oct 22ZYUS Life Sciences Corporation announced that it has received fundingOn October 20, 2025, The company has closed the transaction. The company has amended the terms of the transaction. The company has issued 724,637 common share purchase warrants at an exercise price of $0.69 per common share until the expiry date. he Loan bears interest at an annual rate of 12%, is payable on maturity, is pre-payable by the Company at any time without penalty or premium and will mature on October 31, 2027.
공고 • Oct 03Zyus Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2A Utopia-1 Cancer Pain TrialZYUS Life Sciences Corporation announced the activation of two additional clinical sites in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial. The addition of CancerCare Manitoba ("CCMB") and The Research Institute of the McGill University Health Centre ("The Institute"), along with the Centre Hospitalier de l'Université de Montréal ("CHUM"), expands the Phase 2a UPOPIA-1 trial to three active clinical sites across Canada. UTOPIA-1 is a single-arm, proof-of-concept study designed to evaluate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With three active sites, the trial is positioned to broaden diversity of trial participants and accelerate patient enrollment in the Phase 2a UTOPIA-1 trial evaluating Trichomylin softgel capsules.
공고 • Jul 31ZYUS Life Sciences Corporation announced that it expects to receive CAD 1 million in fundingZYUS Life Sciences Corporation announced a non brokered private placement to issue 1,408,450 Units at a price of CAD 0.71 per unit for aggregate gross proceeds of CAD 999,999.5 on July 29, 2025. Each Unit consists of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. On the same day the company issued 450,281 Units at a price of CAD 0.71 for aggregate proceeds of CAD 319,699.51 in its first tranche. All securities issued in the First Tranche are subject to a hold period expiring November 30, 2025, in accordance with applicable securities laws and the policies of the TSXV.
공고 • Jul 15ZYUS Life Sciences Corporation Appoints Dr. Julie Stakiw, MD, FRCPC as Chief Medical Officer, Effective July 14, 2025ZYUS Life Sciences Corporation announced the appointment of Dr. Julie Stakiw, MD, FRCPC, to the Company's leadership team as Chief Medical Officer (CMO), effective July 14, 2025. Dr. Stakiw is a prominent hematologist-oncologist with over two decades of clinical and academic experience based in Saskatoon, Saskatchewan, specializing in blood cancers and stem cell transplantation. As CMO, Dr. Stakiw will provide clinical leadership and oversee the scientific integrity of ZYUS' clinical development program. Her appointment marks a significant step as the Company advances its lead drug product candidate, Trichomylin® softgel capsules, through its pivotal Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) trial. Dr. Stakiw completed her medical degree and internal medicine residency at the University of Saskatchewan, followed by specialized training in hematology at Queen's University and a clinical fellowship in lymphoma and stem cell transplantation at Princess Margaret Hospital in Toronto. She has held several key leadership positions including Provincial Leader of Hematology, Medical Director of Saskatchewan's Blood and Marrow Transplant Program, and Medical Director of the Saskatoon Cancer Clinic. Dr. Stakiw also previously served as Director of Clinical Trials at a regional cancer centre in Ontario and as Director of Patient Research and Innovation for the Saskatchewan Cancer Agency. Known for her patient-centered approach andexpertise in managing complex hematologic conditions such as multiple myeloma and leukemia, Dr. Stakiw continues to serve as a Clinical Professor in Hematological Oncology at the University of Saskatchewan while maintaining an active clinical practice. Her extensive clinical and leadership experience will be instrumental in advancing ZYUS' clinical development program. Dr. Stakiw succeeds Dr. Lionel Marks de Chabris, who is stepping down as CMO and will continue to provide strategic guidance as Chair of the Clinical Research Advisory Committee. The Company is grateful for Dr. Marks de Chabris's ongoing leadership and commitment to advancing ZYUS' mission.
공고 • Jun 29ZYUS Life Sciences Corporation announced that it has received CAD 0.747899 million in fundingOn June 27, 2025, ZYUS Life Sciences Corporation closed the transaction. The company issued 746,267 units at an issue price of CAD 0.67 for gross proceeds of CAD 499,998.89 in its second and final tranche. The company issued a total of 1,116,267 units at a price of CAD 0.67 per unit for gross proceeds of CAD 747,898.89 in the offering. No finder’s fees were paid in connection with the offering. All securities issued under the second tranche are subject to a hold period expiring October 28, 2025, in accordance with applicable securities laws and the policies of the TSXV. The offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. Certain insiders of the company participated in the offering and acquired 746,267 units for CAD 499,998.89. The offering was approved by the directors of the company who are independent in respect of the offering and who are not employees of the company.
공고 • Jun 17ZYUS Life Sciences Corporation announced that it expects to receive CAD 0.749999 million in fundingZYUS Life Sciences Corporation announced a non-brokered private placement to issue 1,119,402 Units of the company at a price of CAD 0.67 for aggregate gross proceed of CAD 749,999.34. Each Unit consists of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. The transaction is subject to the approval of the TSXV. On the same date, the company issued 370,000 Units at a price of CAD 0.67 for aggregate gross proceeds of CAD 247,900.00 in its first Tranche. All securities issued under the First Tranche are subject to a hold period expiring October 17, 2025.
공고 • May 22Zyus Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain DrugZYUS Life Sciences Corporation announced it is in the process of finalizing site initiation for the initial locations to be used in its Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial. The Phase 2 UTOPIA clinical trial will consist of Phase 2A ("UTOPIA-1") and Phase 2B ("UTOPIA-2). UTOPIA-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin®? softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population. Patient enrollment for UTOPIA-1 is expected to begin in early June 2025, across multiple sites in Canada, with interim data from UTOPIA-1 anticipated mid-summer 2025. ZYUS' announcement comes at a time of growing global recognition of the untapped potential of cannabinoids in oncology. A meta-analysis of medial cannabis outcomes and associations with cancer published in Frontiers in Oncology on April 14, 2025, analyzed over 10,000 peer-reviewed studies encompassing 39,767 data points. The findings revealed a "strong consensus" supporting cannabinoids for managing cancer-related symptoms.
공고 • May 16ZYUS Life Sciences Corporation announced that it has received CAD 1.375 million in fundingOn May 15, 2025, ZYUS Life Sciences Corporation has closed its second and final tranche. The company has issued 871,212 Units at a price of CAD 0.66 per unit for gross proceeds of CAD 574,999.92.The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering is approximately CAD 1,370,000. The Company issued a total of 2,083,333 Units each priced at CAD 0.66 per Unit in the Offering. Each Unit consists of one common share of the Company and one-half of one Common Share purchase warrant, whereby each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.94 for a period of 24 months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. No finder’s fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring September 7, 2025 and all securities issued under the Second Tranche are subject to a hold period expiring September 16, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV.
공고 • May 01ZYUS Life Sciences Corporation announced that it expects to receive CAD 2 million in fundingZYUS Life Sciences Corporation announced a non-brokered private placement to issue up to 3,030,303 units at an issue price of CAD 0.66 per unit for the aggregate gross proceeds of CAD 1,999,999.98 on May 1, 2025. Each unit is comprised of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to acquire one common share at a price of CAD 0.94 for a period of twenty-four months from the date of issuance. No finders fees will be paid in connection with the offering. The transaction is expected to close over multiple tranches as the corporation may determine from time to time, with the first tranche expected to close on or about May 6, 2025. The transaction is subject to customary conditions including, but not limited to, receipt of all necessary TSX Venture Exchange , regulatory and other approvals. Securities offered are subject to hold period of four months plus a day from the date of issuance.
공고 • Apr 21ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2025ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2025.
공고 • Aug 27ZYUS Life Sciences Corporation announced that it has received CAD 3.334828 million in fundingZYUS Life Sciences Corporation announced a non-brokered private placement of 3,510,345 units at a price of CAD 0.95 per unit for the gross proceeds of CAD 3,334,828 on August 26, 2024. Each unit consists of one common share of the company and one common share purchase warrant, whereby each warrant entitles the holder to acquire one common share at a price of CAD 1.30 for a period of twenty-four months from the date of issuance. Insiders of the company, who are independent directors, purchased 842,103 Units pursuant to the private placement for gross proceeds of CAD 800,000. All securities issued pursuant to the Private Placement are subject to a statutory hold period expiring four months plus a day from the date of issuance in accordance with applicable securities legislation in Canada. The Private Placement remains subject to the final acceptance of TSX Venture Exchange (“TSXV”).
공고 • Jun 05ZYUS Life Sciences Receives Cannabis Drug License from Health CanadaZYUS Life Sciences Corporation announced that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a Cannabis Drug License issued pursuant to the Cannabis Act (Canada) and Cannabis Regulations. This license pertains specifically to its processing facility located in Saskatoon, Saskatchewan, which is dedicated to the manufacture of pharmaceutical-grade cannabinoid formulations. Issuance of the Cannabis Drug License compliments ZYUS’ existing standard processing, research, analytical and medical sales licenses and expands the scope of the Company’s license portfolio by enabling ZYUS to manufacture and distribute drugs containing cannabinoids for Health Canada-approved clinical trials in Canada. Advancing Innovation Through Trichomylin Softgel Capsules Phase 2 Clinical Trial: As previously announced, ZYUS intends to launch a Phase 2 Clinical Trial in Canada later this year to assess the preliminary efficacy, safety, and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. ZYUS’ receipt of the Cannabis Drug License and compliance with applicable quality guidelines issued by the International Council for Harmonisation and Good Manufacturing Practice standards provides a robust framework respecting the Company’s manufacture of Trichomylin softgel capsules for its Phase 2 Clinical Trial and brings ZYUS one step closer to achieving its goal of obtaining regulatory approval of its proprietary drug product.
공고 • Apr 14ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2024ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2024. Agenda: Annual General and Special meeting.
공고 • Feb 02Zyus Appoints Dr. Hance Clarke as Clinical Advisory CommitteeZYUS Life Sciences Corporation announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee. Dr. Clarke’s extensive background in healthcare and pain management aligns seamlessly with the committee's mission to provide valuable insights and strategic guidance to ZYUS’ clinical trial programs. Dr. Clarke is internationally recognized for his outstanding contributions to research productivity and advancements in patient care. He holds the positions of Director of Pain Services at the GoodHope Ehlers Danlos Clinic and the Pain Research Unit at Toronto General Hospital. Additionally, he serves as associate professor in the Department of Anesthesiology and Pain Medicine at the University of Toronto. In his capacity as the Knowledge Translation Chair for the University of Toronto Centre for the Study of Pain, Dr. Clarke demonstrates a strong commitment to advancing the understanding and application of pain research. With over 170 peer-reviewed publications to his credit, he currently holds the position of president-elect of the Canadian Pain Society and serves as the president of the Canadian Consortium for the Investigation of Cannabinoids. Dr. Clarke has also played a leading role in educating the Canadian public about pain control, risk factors for chronic opioid use, alternatives to opioids and the need for further studies on understanding the beneficial and adverse effects of cannabis. Being a public champion of evidence-based solutions for the opioid crisis and a national pain and addictions strategist, Dr. Clarke’s appointment aligns with ZYUS’ clinical research initiatives and his influential insights in this field will offer valuable guidance to further enhance ZYUS’ clinical programs. Dr. Clarke joins previously-appointed Advisory Committee members: ZYUS’ Chief Medical Officer, Dr. Lionel Marks de Chabris, Chair of the Committee; Dr. Mary Lynch, Director of Research at the Pain Management Unit at the Queen Elizabeth II Health Sciences Centre; Dr. Cedric Francois, Co-Founder, Chief Executive Officer and President of Apellis Pharmaceuticals; Dr. Alice Zwerling, Assistant Professor in the School of Epidemiology and Public Health in the Faculty of Medicine at the University of Ottawa; and, Ms. Audrey Haukioja, a seasoned executive with over 25 years of experience in the pharmaceutical field, specializing in clinical trials and drug development.
공고 • Dec 05ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain ManagementZYUS Life Sciences Corporation announced that it has made the strategic decision to proceed with a Phase 2 Clinical Trial in Canada to assess the preliminary efficacy, safety and tolerability of Trichomylin®? softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Transitioning to Phase 2 Clinical Trial for Trichomylin Softgels: Initially planned as a Phase 2a Clinical Trial, ZYUS has made the strategic decision to fast-track and progress directly to a full Phase 2 Clinical Trial following receipt of positive results from its Phase 1, first-in-human clinical trial testing the safety and tolerability of Trichomylin softgel capsules. While a Phase 2a Clinical Trial could have provided preliminary efficacy data for Trichomylin softgels, it would not have generated the data required by regulatory agencies in Canada and the U.S. to formally commence the regulatory drug approval process and, therefore, completion of a Phase 2b clinical trial would have been necessary. In addition to efficiently building shareholder value, ZYUS believes advancing directly to a full Phase 2 Clinical Trial will also reduce the time and cost associated with obtaining regulatory approval of Trichomylin softgel capsules and delivering this important therapeutic to patients in need. Phase 2 Clinical Trial Structure: ZYUS has selected a leading, full-service Canadian contract research organization with extensive clinical trial management experience to conduct its Phase 2 Clinical Trial. ZYUS anticipates the trial will be structured as a double-blinded, placebo-controlled, randomized, multiple dose escalation study that will enroll a total of up to 126 patients with advanced cancer and moderate to severe cancer-related pain. The company plans to recruit patients at six Canadian investigative sites, with patients being randomized at a 1:1 ratio with approximately 63 patients in each arm.
공고 • Nov 24ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® SoftgelsZYUS Life Sciences Corporation announced receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (“FIH”) Clinical Trial for its lead drug product candidate, Trichomylin® softgels.
공고 • Oct 25ZYUS Life Sciences Corporation Appoints Tim Miller as Director of Investor Relations and Capital Markets, Effective November 1, 2023ZYUS Life Sciences Corporation announced that Tim Miller is joining the Company as Director of Investor Relations and Capital Markets, effective November 1, 2023. Mr. Miller will be based out of the Company’s Toronto office and brings a wealth of knowledge, experience and expertise to his new role with ZYUS, making him a valuable addition to the team. Mr. Miller is a distinguished professional with a Bachelor of Commerce degree from Ryerson University, boasting an impressive track record of nearly two decades as a capital markets executive. His core focus has been Institutional Equity Sales, and his expertise extends across a broad spectrum of clients. These encompass a wide range, from US and Canadian family offices to hedge funds, pension funds, mutual funds, venture capital firms, and private equity investors.
공고 • Sep 02ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member, Wayne Brownlee and Announces Reconstitution of its Board CommitteesZYUS Life Sciences Corporation announced that Wayne Brownlee, who was conditionally appointed to the Company’s Board of Directors on June 28, 2023, has successfully obtained from Health Canada security clearance required to serve as a director of the Corporation pursuant to the Cannabis Act (Canada). With the appointment of Wayne Brownlee taking effect, the Company’s Board of Directors reconstituted its board committees as follows: Audit Committee: John Knowles (Chair), Garnette Weber and Wayne Brownlee. Compensation Committee: Garnette Weber (Chair), Richard Hoyt and Dr. Charlotte Moore Hepburn. Governance and Nominating Committee: Richard Hoyt (Chair), John Knowles, Brent Zettl and Wayne Brownlee.